Cargando…
Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health
As part of an increasing worldwide use of designer drugs, recent use of compounds containing cathinones and synthetic cannabinoids is especially prevalent. Here, we reviewed current literature on the prevalence, epidemiology, bio-behavioral effects, and detection of these compounds. Gender differenc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572353/ https://www.ncbi.nlm.nih.gov/pubmed/28878698 http://dx.doi.org/10.3389/fpsyt.2017.00156 |
_version_ | 1783259509973581824 |
---|---|
author | Weinstein, Aviv M. Rosca, Paola Fattore, Liana London, Edythe D. |
author_facet | Weinstein, Aviv M. Rosca, Paola Fattore, Liana London, Edythe D. |
author_sort | Weinstein, Aviv M. |
collection | PubMed |
description | As part of an increasing worldwide use of designer drugs, recent use of compounds containing cathinones and synthetic cannabinoids is especially prevalent. Here, we reviewed current literature on the prevalence, epidemiology, bio-behavioral effects, and detection of these compounds. Gender differences and clinical effects will also be examined. Chronic use of synthetic cathinone compounds can have major effects on the central nervous system and can induce acute psychosis, hypomania, paranoid ideation, and delusions, similar to the effects of other better-known amphetamine-type stimulants. Synthetic cannabinoid products have effects that are somewhat similar to those of natural cannabis but more potent and long-lasting than THC. Some of these compounds are potent and dangerous, having been linked to psychosis, mania, and suicidal ideation. Novel compounds are developed rapidly and new screening techniques are needed to detect them as well as a rigorous regulation and legislation reinforcement to prevent their distribution and use. Given the rapid increase in the use of synthetic cathinones and cannabinoid designer drugs, their potential for dependence and abuse, and harmful medical and psychiatric effects, there is a need for research and education in the areas of prevention and treatment. |
format | Online Article Text |
id | pubmed-5572353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55723532017-09-06 Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health Weinstein, Aviv M. Rosca, Paola Fattore, Liana London, Edythe D. Front Psychiatry Psychiatry As part of an increasing worldwide use of designer drugs, recent use of compounds containing cathinones and synthetic cannabinoids is especially prevalent. Here, we reviewed current literature on the prevalence, epidemiology, bio-behavioral effects, and detection of these compounds. Gender differences and clinical effects will also be examined. Chronic use of synthetic cathinone compounds can have major effects on the central nervous system and can induce acute psychosis, hypomania, paranoid ideation, and delusions, similar to the effects of other better-known amphetamine-type stimulants. Synthetic cannabinoid products have effects that are somewhat similar to those of natural cannabis but more potent and long-lasting than THC. Some of these compounds are potent and dangerous, having been linked to psychosis, mania, and suicidal ideation. Novel compounds are developed rapidly and new screening techniques are needed to detect them as well as a rigorous regulation and legislation reinforcement to prevent their distribution and use. Given the rapid increase in the use of synthetic cathinones and cannabinoid designer drugs, their potential for dependence and abuse, and harmful medical and psychiatric effects, there is a need for research and education in the areas of prevention and treatment. Frontiers Media S.A. 2017-08-23 /pmc/articles/PMC5572353/ /pubmed/28878698 http://dx.doi.org/10.3389/fpsyt.2017.00156 Text en Copyright © 2017 Weinstein, Rosca, Fattore and London. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Weinstein, Aviv M. Rosca, Paola Fattore, Liana London, Edythe D. Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health |
title | Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health |
title_full | Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health |
title_fullStr | Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health |
title_full_unstemmed | Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health |
title_short | Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health |
title_sort | synthetic cathinone and cannabinoid designer drugs pose a major risk for public health |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572353/ https://www.ncbi.nlm.nih.gov/pubmed/28878698 http://dx.doi.org/10.3389/fpsyt.2017.00156 |
work_keys_str_mv | AT weinsteinavivm syntheticcathinoneandcannabinoiddesignerdrugsposeamajorriskforpublichealth AT roscapaola syntheticcathinoneandcannabinoiddesignerdrugsposeamajorriskforpublichealth AT fattoreliana syntheticcathinoneandcannabinoiddesignerdrugsposeamajorriskforpublichealth AT londonedythed syntheticcathinoneandcannabinoiddesignerdrugsposeamajorriskforpublichealth |